BioMarin Pharmaceutical Inc (BMRN)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$52.50

Buy

$54.00

arrow-up$0.32 (+0.60%)

Prices updated at 12 Dec 2025, 23:29 EST

Prices minimum 15 mins delay

Prices in USD

Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Richard A. Meier

CEO

Mr. Alexander Hardy

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

3,040

Head office

770 Lindaro Street

San Rafael

United States

94901

+1 415 506-6700

ir@bmrn.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Ian T. Clark Independent Director	-
Mr. Timothy P. Walbert Independent Director	-
Mr. Brian R. Mueller Executive Vice President ,Chief Financial Officer and Principal Accounting Officer	0.70m
Mr. Richard A. Meier Chairman of the Board	0.17m
Dr. Willard H. Dere, M.D. Independent Director	0.10m
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary	0.72m
Mr. Robert J. Hombach Independent Director	0.10m
Dr. Athena Countouriotis, M.D. Independent Director	0.08m
Mr. Mark Joseph Enyedy Independent Director	0.10m
Dr. Maykin Ho, PhD Independent Director	0.10m
Ms. Barbara W. Bodem Independent Director	0.10m
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director	0.10m
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President	-
Mr. Alexander Hardy Director, President and Chief Executive Officer	1.05m
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer	0.38m
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer	0.16m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	22,046,050
Vanguard Group Inc	19,003,832
PRIMECAP Management Company	15,229,287
Dodge & Cox	14,686,801
BlackRock Fund Advisors	11,012,691

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Nov 2024	-
31 Oct 2024	-
12 Nov 2024	-
31 Oct 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
13 Sep 2024	-
30 Apr 2024	-
13 Aug 2024	-
28 Jun 2024	-
03 Jun 2024	-
03 Jun 2024	-
03 Jun 2024	-
03 Jun 2024	-
03 Jun 2024	-
03 Jun 2024	-
30 May 2024	-
30 May 2024	-
30 May 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.